Navigation Links
Pharsight Achieves $7.6 Million In Quarterly Revenue
Date:5/8/2008

included in the tables attached to this press release and on Pharsight's website under the Investor Relations section.

Cash & Liquidity

Pharsight exited the fourth fiscal quarter with cash, cash equivalents and short-term investments of $17.1 million compared with $14.7 million at the end of fiscal 2007.

Fiscal 2009 Guidance

The Company is issuing the following guidance for fiscal 2009:

-- Annual revenue growth of approximately 13% to 18% compared with fiscal

2008, or approximately $32 to $33.5 million.

-- Gross margin of approximately 64% to 66% of revenue, depending on the

revenue mix between software, software services and consulting

services.

-- Non-GAAP net income, excluding non-cash expenses associated with

stock-based compensation expense of approximately 11% to 13% of revenue

with non-GAAP fully diluted EPS of approximately $0.34 to $0.41.

-- GAAP net income of approximately 7% to 9% of revenue with GAAP fully

diluted EPS of approximately $0.21 to $0.29.

-- Positive annual net cash flow

"We are very proud of what we set out to achieve and executed during fiscal 2008," said Will Frederick, senior vice president and chief financial officer. "We performed to our annual guidance originally provided at the beginning of the fiscal year, paid off all our debt and successfully re-listed our common stock on the Nasdaq Capital Market. Additionally, our preferred shareholders converted their shares into common stock, relieving the company of the quarterly dividend liability. This year marked our 5th consecutive year of annual revenue growth and our 4th consecutive year of profitability and positive annual net cash flow. As we enter the FY09 fiscal year, we have cash equivalents and short-term investments in excess of $17 million, with no outstanding debt and a $5 million available credit facility."

While Pharsight expects that over the lo
'/>"/>

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Pharsight Signs Two New DMX(R) License Customers
2. Pharsight to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference
3. Pharsight Makes Strong Contribution to Inaugural American Conference on Pharmacometrics
4. Pharsights Reporting and Analysis Services Business Unit to Leverage New Validated Data Management System
5. Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer
6. Pharsight to Present at Jesup and Lamont 2008 Emerging Growth Stock Conference
7. Pharsight Achieves $7.4 Million in Quarterly Revenue
8. Pharsight Announces Fiscal Third Quarter 2008 Earnings Release Date and Conference Call
9. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
10. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
11. Pharsight Announces 1-For-3 Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... If you plan to attend the ... October, you will also want to sign up for the tour of Framingham State ... tour includes a walk through of the (8) chemistry teaching labs that are exclusively ...
(Date:9/2/2015)... Sept. 2, 2015 Research and ... addition of Jain PharmaBiotech,s new report ... their offering. An increasing ... biotechnology industries is anticipated. Nanotechnology will be ... - from formulations for optimal delivery to ...
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report ... of sequencing technologies, and their applications. Current large ... companies developing them. Various applications of sequencing are ...
(Date:9/2/2015)... ... September 02, 2015 , ... The wet ... use of special anti-vascular endothelial growth factor agents given by injection into the ... not have a scientific protocol for the many millions diagnosed with it. AMD ...
Breaking Biology Technology:Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2
... , INDIANAPOLIS, Dec. 16 /PRNewswire/ ... Indiana,s life sciences industry and an active venture capital market, ... Retirement Fund, Indiana University, Purdue University, the University of Notre ... the establishment of the INext Fund, a $58 million venture ...
... , , Toronto biotechnology company,s revenues increase ... flow in fiscal 2010 , TORONTO, Dec. 16 /PRNewswire-FirstCall/ ... on virology and biological technologies, today reported financial results ... year ended September 30, 2009, Microbix reported revenues of ...
... , Trial conducted pursuant to Special Protocol Assessment with ... 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ... focused on oncology and endocrine therapy, today announced the ... KERX), of a Phase 3 registration clinical trial for ...
Cached Biology Technology:Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5Microbix' Pipeline Set To Reach Milestones In 2010 2Microbix' Pipeline Set To Reach Milestones In 2010 3Microbix' Pipeline Set To Reach Milestones In 2010 4Microbix' Pipeline Set To Reach Milestones In 2010 5Microbix' Pipeline Set To Reach Milestones In 2010 6Microbix' Pipeline Set To Reach Milestones In 2010 7Microbix' Pipeline Set To Reach Milestones In 2010 8AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5
(Date:8/24/2015)... , Aug. 24, 2015  Based on its recent analysis ... with the 2015 African Biometrics Company of the Year Award. ... substantial commercial success in Africa . It ... where it has implemented one of the largest biometric mass ... well as the Central Bank of Nigeria ...
(Date:8/19/2015)... N.Y. , Aug. 19, 2015  VOXX ... that it has entered into a Definitive Agreement ... property, of iris authentication market leader EyeLock through ... VOXX will have a controlling interest in the ... subject to completion of due diligence.  Expanding on ...
(Date:8/12/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is proud to announce that iMedNet ... platform, has led the way to significant and unprecedented ...   Q2 2015 and Q1 2015 were, respectively, the ... sold in the company,s 15 year history.  In addition, ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2
... Survival Alliance (TSA) and Wildlife Conservation Society (WCS) reported today ... beautiful tortoise species is rapidly nearing extinction due to ... The team predicts that unless drastic conservation measures take ... next 20 years. The team recently returned from ...
... CORVALLIS, Ore. The Swiss needle cast epidemic in Douglas-fir ... appears to be unprecedented over at least the past 100 ... Douglas-fir along the coast and a warmer climate, new research ... State University have also found that this disease, which is ...
... dangerous Cryptococcus fungi love sugar and will consume ... they thrive on a sugar called inositol which is ... borrow inositol from a person,s brain, the fungi have an ... While a typical fungus has just two such genes, ...
Cached Biology News:Madagascar's radiated tortoise threatened with extinction 2Madagascar's radiated tortoise threatened with extinction 3Forest epidemic is unprecedented phenomenon, still getting worse 2Forest epidemic is unprecedented phenomenon, still getting worse 3Forest epidemic is unprecedented phenomenon, still getting worse 4This is your brain on Cryptococcus: Pathogenic fungus loves your brain sugar 2
...
QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Biology Products: